ROS Kinase

跨膜原癌基因受体酪氨酸激酶 (RTK) ROS 是最后两种孤儿受体酪氨酸激酶之一。其正常表达模式在发育过程中受到严格的时空限制。据报道,ROS 激酶的异位表达以及可变突变形式的产生在许多癌症中都有报道,例如多形性胶质母细胞瘤和非小细胞肺癌,这表明 ROS 激酶在衍生此类肿瘤方面发挥着作用。人们还认为 c-ROS 基因可能在某些心血管疾病中发挥作用,而针对 c-ROS 基因的纯合雄性小鼠虽然健康但不育,这一事实启发研究人员考虑将 ROS 抑制作为开发新型男性避孕药的方法。

ROS1 是一种跨膜受体酪氨酸激酶原癌基因,已证明其与胶质母细胞瘤、非小细胞肺癌 (NSCLC) 和其他肿瘤中的几种基因发生重排,包括由于 6q22.1 处的微缺失而与 GOPC 发生染色体内融合。ROS1 融合事件是这些肿瘤中的重要发现,因为它们可能是新型酪氨酸激酶抑制剂的靶向改变。

The transmembrane proto-oncogene receptor tyrosine kinase (RTK) ROS is one of the last two remaining orphan receptor tyrosine kinases. Its normal expression pattern is tightly spatiotemporally restricted during development. The ectopic expression, as well as the production of variable mutant forms of ROS kinase, has been reported in a number of cancers, such as glioblastoma multiforme, and non-small cell lung cancer, suggesting a role for ROS kinase in deriving such tumors. It is thought also that the c-ROS gene may have a role in some cardiovascular diseases, and the fact that homozygous male mice targeted against the c-ROS gene are healthy but infertile has inspired researchers to think about ROS inhibition as a method for the development of new male contraceptives.

ROS1 is a transmembrane receptor tyrosine kinase proto-oncogene that has been shown to have rearrangements with several genes in glioblastoma, non-small-cell lung cancer (NSCLC), and other neoplasms, including intrachromosomal fusion with GOPC due to microdeletions at 6q22.1. ROS1 fusion events are important findings in these tumors, as they are potentially targetable alterations with newer tyrosine kinase inhibitors.

共 1种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
SIA​​IS039

SIAIS039 是一种具有口服活性的 c-ros 致癌基因 1 (ROS1) 特异性 PROTAC,在 HCC78 细胞、表达 CD74-ROS1 融合的 Ba/F3 和表达 SDC4-ROS1 融合的 Ba/F3 中的 DC50 分别为 154.46 nM、126.47 nM 和 143.69 nM,可抑制 ROS1 阳性细胞增殖、诱导周期停滞和凋亡、抑制克隆形成,并在体内显示出对 ROS1 驱动的肿瘤生长的抑制作用,其由 ALK 抑制剂 Brigatinib (MS-T97165)、linker EM-12 (MS-B84852) 和 VHL E3 泛素连接酶配体组成 (Red: Brigatinib; Blue: VHL ligand; Black: linker)。

2570251-69-1
Degrader
99.68%
SIA​​IS039

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础